Elevance Health Inc.
ELV Healthcare Medical - Healthcare Plans NYSE
$373.97
+$2.91 (+0.78%)
Open: $370.73 | High: $374.31 | Low: $367.88 | Prev Close: $371.06
Market Cap: $83.11B
Volume: 427K | Avg: 1.5M
Last updated: January 26, 2026 at 06:02 PMInvestment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 485
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 15.25 |
| P/B Ratio | 1.92 |
| P/S Ratio | 0.43 |
| EPS | $24.53 |
| Beta | 0.52 |
| Shares Outstanding | 222.24M |
| 52-Week High | $458.75 |
| 52-Week Low | $273.71 |
| SMA 50 | $347.09 |
| SMA 200 | $349.31 |
| Dividend Yield | 1.83% |
| Annual Dividend | $6.84 |
| Next Earnings | January 28, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 77.7% |
| Operating Margin | 3.8% |
| Net Margin | 2.8% |
| ROE | 12.9% |
| ROA | 4.5% |
| Debt/Equity | 0.73 |
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
Balance Sheet
| Total Assets | $116.89B |
| Total Liabilities | $75.46B |
| Total Equity | $41.31B |
|
|
|
| Cash | $8.29B |
| Total Debt | $31.23B |
| Net Debt | $22.94B |
Income Statement
| Revenue | $176.81B |
| Gross Profit | $176.81B |
| Operating Income | $7.90B |
| Net Income | $5.98B |
|
|
|
| EBITDA | $10.48B |
| Revenue/Share | $862.80 |
Cash Flow
| Operating CF | $5.81B |
| CapEx | $1.26B |
| Free Cash Flow | $4.55B |
|
|
|
| Book Value/Share | $195.23 |
| Tangible Book/Share | $19.06 |
| Equity/Share | $194.65 |
Technical Indicators
| RSI (14) | 50.00 Neutral |
| MACD |
0.00
Signal: 0.00
|
| Volatility | 0.00% |
| Trading Signal | Neutral |
Performance & Returns
Insufficient historical data
Insufficient historical data (need 200+ days, have 0)Sector Comparison (Healthcare)
| Metric | ELV | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 15.25 | 35.75 | 23% |
| P/B Ratio | 1.92 | 0.23 | 26% |
| ROE (%) | 12.91% | 14.20% | 39% |
| Net Margin (%) | 2.84% | 9.80% | 22% |
| Stock Score | 485 | 468.0 | 48% |
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELV | $373.97 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | 50.00 | 0.00 | 0.00% | 0 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the ELV stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| ELV | Barlow Wealth Partners Inc. Trims Stock Position in Elevance Health, Inc. $ELV | Neutral | defenseworld.net | Read More |
| ELV | Health insurers tumble after Trump administration proposes keeping Medicare Advantage rates flat next year | Neutral | cnbc.com | Read More |
| ELV | Trump Administration proposes keeping steady Medicare rates paid to insurers, WSJ reports | Neutral | reuters.com | Read More |
| ELV | Simplicity Wealth LLC Reduces Position in Elevance Health, Inc. $ELV | Neutral | defenseworld.net | Read More |
| ELV | FSB Premier Wealth Management Inc. Has $1.79 Million Stock Position in Elevance Health, Inc. $ELV | Neutral | defenseworld.net | Read More |
Recent Insider Trading
No recent insider trading data available for ELV
Company Information
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
| CEO | Gail Koziara Boudreaux |
| Employees | 104200 |
| Country | US |
| IPO Date | 2001-10-30 |
| Exchange | NYSE |
| Website | https://www.elevancehealth.com |
| Sector | Healthcare |
| Industry | Medical - Healthcare Plans |
Similar Stocks (Healthcare - Medical - Healthcare Plans)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category